GlobeNewswire

Elastic Acquires SaaS Site Search Leader Swiftype

Dela

Swiftype's Site Search and Enterprise Search products further extend Elastic's vision to offer tailored solutions on top of the Elastic Stack

MOUNTAIN VIEW, Calif. and AMSTERDAM, The Netherlands, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Elastic, the company behind Elasticsearch, and the Elastic Stack, the most widely-used collection of open source products for solving mission-critical use cases like search, logging, and analytics, today announced that it has acquired Swiftype, a San Francisco-based startup founded in 2012 and backed by Y Combinator and New Enterprise Associates (NEA). Swiftype is the creator of the popular SaaS-based Site Search and the recently introduced Enterprise Search products.

Swiftype is an early adopter of Elasticsearch, using Elasticsearch to index and store searchable content and power the search experience for its Site Search product. Used by more than 900 organizations including Asana, AT&T, Dr. Pepper, Engadget, Hubspot, Marketo, Shopify, SurveyMonkey, and TechCrunch, Site Search offers users the ability to create customized search experiences; a user interface to configure advanced features, such as relevance, autocomplete, faceted search, and custom result ranking; and real-time analytics, reports, and dashboards. Effective immediately, Swiftype's Site Search product will be offered with a new introductory subscription plan starting at $79/month that allows customers to grow at their own pace. In addition, Site Search provides a straightforward migration path for Google Site Search (GSS) customers.

Released earlier this year, Swiftype's Enterprise Search product helps organizations manage content across disparate data sources and seamlessly connect to cloud-based applications like Atlassian, Box, Dropbox, Github, Google Apps, Microsoft Outlook, Salesforce, Slack, Zendesk, and more. Effectively immediately, Enterprise Search will be moved to beta and available for trial upon request. The combined Elastic and Swiftype engineering teams will integrate more capabilities of the Elastic Stack and X-Pack into Enterprise Search and will make it available as both as a hosted service and on-premise solution.

"We've long invested in Elasticsearch to help power the Swiftype platform, given its superior technology for building real-time and scalable search solutions," said Matt Riley, Swiftype Co-Founder and CEO. "Joining forces with the Elastic team and merging our collective best-in-class solutions will drive success for customers, making way for natural opportunities for new and improved products and solutions."

"Swiftype has built an amazing company and a rich set of SaaS products leveraging the power of Elasticsearch as a generic search engine," said Shay Banon, Elastic Founder and CEO. "By joining forces with Swiftype, our customers will be able to address their simple website or application search needs, and in the future, more complex enterprise search use cases with a highly tailored and curated SaaS or on-premise experience."

Learn More

About Elastic
Elastic builds software to make data usable in real time and at scale for search, logging, security, and analytics use cases. Founded in 2012, the company develops the open source Elastic Stack (Elasticsearch, Kibana, Beats, and Logstash), X-Pack (commercial features), and Elastic Cloud (a hosted offering). To date, there have been more than 150 million cumulative downloads. Backed by Benchmark Capital, Index Ventures, and NEA with more than $100 million in funding, Elastic has a distributed workforce with more than 600 employees in 30 countries. Learn more at elastic.co

Elastic Media Contacts:
AMER
Michael Lindenberger
Reidy Communications for Elastic
michael@reidycommunications.com 
+1-415-531-1449

EMEA
Rory MacDonald
Age of Peers Ltd for Elastic
rory@ageofpeers.com 
+44 (0)7899 965232




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Elastic via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum